Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus

Lancet

Volumn 348, Issue 9035, 1996, Pages 1120-1124

  Petri, Michelle ^a   Roubenoff, Ronenn ^b,c   Dallal, Gerard E ^b   Nadeau, Marie R ^b   Selhub, Jacob ^b   Rosenberg, Irwin H ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXAL 5 PHOSPHATE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VITAMIN BLOOD LEVEL;

EID: 0030603334     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)03032-2     Document Type: Article

References (29)

1. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: A study of 36 necropsy patients. Am J Med 1975; 58: 243-64.
2. Brown JH, Doherty CC, Allen DC, Morton P Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. BMJ. 296:1988;1505.
3. Kattwinkel N, Villanueva AG, Labib SB, et al. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. Ann Intern Med 1992; 116: 974-76.
4. Cumming RG, Barton GE, Fahey PP, Wilson A, Leeder SR. Cardiovascular disease-related knowledge and attitudes in a high-risk Australian population. Med J Aust 1989; 150: 551-58.
5. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-19.
6. Linder MC. Nutrition and metabolism of vitamins. In: Linder MC, ed. Nutritional biochemistry and metabolism, 2nd edn. New York: Elsevier, 1991: 127-37.
7. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
8. Harper AE, Benevenga NJ, Wohlheuter RM Effects of ingestion of disproportionate amounts of amino acids. Physiol Rev. 50:1970;428-558.
9. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909-16.
10. Tsai J-C, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-73.
11. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RBJ, ed. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker, 1989: 182-236.
12. Stampfer MJ, Malinow MR, Willett WC, et al. A propective study of plasma homocyst(e)ine and risk of myocardal infarction in US physicians. JAMA 1992; 268: 877-81.
13. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-91.
14. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in midde-aged British men. Lancet 1995; 346: 1395-98.
15. National Institutes of Health Consensus Development Panel on the Health Implications of Obesity. Health implications of obesity. Ann Intern Med 1985; 103: 1073-77.
16. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57.
17. Araki A, Sako Y Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 422:1987;43-52.
18. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-98.
19. Camp VM, Chipponi J, Faraj BA. Radioenzyme assay for direct measurement of plasma pyridoxal 5′-phosphate. Clin Chem 1983; 29: 642-44.
20. Tamura T, Freeberg LE, Cornwell PE Inhibition by EDTA of growth of Lactobacillus casei in the folate microbiological assay and its reversal by added manganese or iron. Clin Chem. 36:1990;1993.
21. Petri M, Nelson L, Weimer F, Anderson D, Darlington T, Corash L. The automated modified Russell viper venom time test for the lupus anticoagulant. J Rheumatol 1991; 18: 1923-25.
22. Petri M, Rheinschmidt M, Whiting-O'Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus: A study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody. Ann Intern Med 1987; 106: 524-31.
23. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-57.
24. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-77.
25. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
26. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 25: 1924-30.
27. Russell RM, Suter PM Vitamin requirements of elderly people: an update. Am J Clin Nutr. 58:1993;4-14.
28. Roubenoff R, Moyer M, Drew H, Petri M, Whiting-O'Keefe Q, Hellmann DB. Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis. Ann Intern Med 1990; 113: 501-06.
29. den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-85.